Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma

BACKGROUND: Sorafenib is an orally available kinase inhibitor with activity at Raf, PDGFβ and VEGF receptors that is licensed for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Current evidence-based post-nephrectomy management of individuals with localized...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Fairfax, BP, Pratap, S, Roberts, ISD, Collier, J, Kaplan, R, Meade, AM, Ritchie, AW, Eisen, T, Macaulay, VM, Protheroe, A
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2012
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3575366/
https://ncbi.nlm.nih.gov/pubmed/23231599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-590
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars